

NPCA Newsletter, October 2023

Newsletter highlights:

- 1 NPCA has joined NATCAN
- 2 NPCA scoping meeting
- 3 Methodological update


NPCA joined NATCAN on 1st July 2023

On Saturday 1st July, the NPCA officially joined NATCAN, the National Cancer Audit Collaborating Centre. Alongside six newly commissioned audits (primary and metastatic breast cancer, kidney, ovarian and pancreatic cancer, and non-Hodgkin lymphoma), and two existing audits, bowel and oesophago-gastric, this brings the number of NATCAN audits to nine.



Our Annual Reports will be replaced with State of the Nation reports, with the first one published in January 2024. These will be more concise, limited to 10 performance indicators and five national recommendations.

Additionally, quarterly updates of our performance indicators for each participating Trust will be published on our website using the Rapid Cancer Registration Dataset. Peer reviewed publications across a range of topics arising from the audit will continue. There will be a renewed focus on quality improvement and feedback to sites, with the aim of closing the audit loop.



NPCA held a scoping meeting in May 2023

The NPCA held a scoping meeting bringing together stakeholders and our Clinical Reference Group to discuss the scope of work for the NPCA in its new term.

The NPCA will continue to ensure it considers the needs of stakeholders whilst driving local and national quality improvement in services and outcomes for prostate cancer patients. During the scoping meeting we:

- Assessed the current performance indicators
- Updated the suite of performance indicators
- Determined which data sources provide required information
- Reviewed and updated the healthcare quality improvement plan

Prostate cancer care evolves constantly, so we will explore the imaging processes used in diagnostic and staging processes, the active surveillance protocols followed, as well as examining the radical treatments patients receive and treatments for (oligo)metastatic disease.

Methodological update

In this methodological update we compare the National Cancer Registration Dataset (NCRD) and the Rapid Cancer Registration Dataset (RCRD) for four NPCA performance indicators.

This report shows that there is scope for more timely reporting of prostate cancer services using the RCRD, and that informative performance indicators can be obtained. However, data quality issues, including poor completeness of disease staging data, limit the reliability of indicators.

If you would like to receive **information about the new NATCAN audits** (breast, ovarian, pancreatic and kidney cancer and non-Hodgkin lymphoma), please email natcan@rcseng.ac.uk, indicating which audit(s) you are interested in.